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http://dx.doi.org/10.1016/j.bgm.201Abstract Ethanol consumption during pregnancy is a widespread problem and is increasing
globally among young women. Development of biomarkers of fetal alcohol syndrome (FAS),
which can identify children at risk, may lead to interventions earlier in life. In addition, animal
models of fetal alcohol spectrum disorders can help in novel biomarker discovery. Biomarkers
of fetal alcohol spectrum disorders include classical biomarkers of alcohol-induced pathology
(mean corpuscular volume, g-glutamyl transferase, aspartate aminotransferase, and alanine
aminotransferase), acetaldehyde-derived conjugates, and derivatives of nonoxidative ethanol
metabolism (fatty acid ethyl esters, ethyl glucuronide, ethyl sulfate, and phosphatidyl
ethanol). Because ethanol and acetaldehyde levels can be measured in blood, urine, and sweat
a few hours after ethanol intake, these can be used to detect recent ethanol exposure. Mag-
netic resonance spectroscopic (MRS) biomarkers include N-acetyl aspartate, an indicator of
neuronal density; choline, a precursor of the neurotransmitter; acetyl choline, implicated in
learning and memory and in the synthesis of glycerophosphocholine (involved in membrane
synthesis); and glutamate that is reduced in FAS. Glutamate is a precursor for the synthesis
of g-amino butyric acid, and creatine is required for high-energy phosphate synthesis. Further-
more, reduced brain-derived neurotropic factor, somatostatin, complexin, taurine, gluta-
thione, myoinositol, leptin, and increased insulin-like growth factor and N-methyl D-aspartic
acid receptor toxicity are observed in FAS. Impaired methionineehomocysteine cycle may also
have deleterious effects on protein, DNA, and histone methylation in FAS. In addition to meco-
nium fatty acid ethyl esters, magnetic resonance imaging, positron emission tomography, and
single-photon-emission computerized tomography facilitate an earlier diagnosis of less
alcohol-related disabilities that cannot be confirmed in the absence of a maternal drinking his-
tory. Brain volume, cortical volume, and cortical surface area are also reduced following pre-
natal exposure to ethanol. Hence, discovery of novel biomarkers is needed to define
behavioral, physical, and genetic factors for better clinical management of FAS.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.School of Medicine, Plaza Juliana 4, Kralendijk, Bonaire, Dutch Caribbean, The Netherlands.
.org (S. Sharma).
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Alcohol and several other drugs are frequently abused
alone or in combination across the globe.1 Ethanol is the
most widely used drug of abuse and a teratogen whose
consumption among women of childbearing age is
increasing gradually. Fetal alcohol spectrum disorder
(FASD) is a developmental disorder that affects up to 0.2%
of births. Because both fetal alcohol syndrome (FAS) and
fetal alcohol effect represent preventable causes of mental
retardation and birth defects, detection of alcohol abuse
during pregnancy is essential to avoid deleterious conse-
quences on fetal brain development. A considerable
amount of work is required to extend the knowledge on
fetal alcohol effects among women of childbearing age.
Moreover, awareness and training among health care pro-
fessionals may play significant roles in the early diagnosis of
these devastating conditions.
Alcohol consumption during the gestational period cau-
ses fetal alcohol exposure and is associated with the onset
of FASD, including FAS. FASD and FAS can lead to physical,
cognitive, and behavioral disabilities, whose early diagnosis
is important to accomplish primary prevention with total
abstinence from alcohol during pregnancy and secondary
prevention in newborns and children with regular follow-
ups to reduce the risk of secondary consequences. In recent
years, efforts have been made to understand molecular
mechanisms of FAS and identify biological and diagnostic
tools, such as biomarkers in neonatal meconium and mag-
netic resonance imaging (MRI). However, further studies
are needed to extend the knowledge on fetal effects of
ethanol, and multidisciplinary approaches are necessary to
raise awareness among women of childbearing age about
the dangers of consuming even a small amount of alcohol
during pregnancy.2 Deleterious consequences of FAS are
well established; as a leading cause of intellectual impair-
ments, it has social and public health impact as FAS is
associated with several neurobehavioral deficits.3 FAS is the
most serious consequence of prenatal ethanol exposure,
and individuals who do not meet diagnostic criteria for FAS
are also influenced by gestational ethanol exposure. The
term FASD is used to cover a spectrum of effects that in-
cludes FAS as well as alcohol-related neurodevelopmental
disorder and alcohol-related birth defects. The term
alcohol-related neurodevelopmental disorder refers to a
condition in which individuals, after heavy prenatal alcohol
exposure, exhibit neurobehavioral deficits without meeting
the physical criteria of FAS.4,5 Clinical identification of this
group is difficult because it does not exhibit typical physical
features of FAS, and physiological biomarkers of gestational
alcohol exposure have limitations. Hence, determination of
a profile, based on the neurobehavioral effects of prenatal
alcohol exposure, would allow accurate identification of
FAS and affected individuals. The development of such a
profile is aimed at identifying and characterizing those who
are affected by prenatal alcohol exposure, and not only
those who have been exposed to alcohol prenatally.6,7
Acquiring information about drinking during pregnancy is
one of the most challenging areas of the study on FASD,
because these children are difficult to differentiallydiagnose, treat, and confirm whether or not their mothers
consumed alcohol during pregnancy. Currently available
screening questionnaires to diagnose and confirm FASD are
unreliable, and biomarkers are insensitive for pregnant
women. Hence, there is a dire need to discover novel bio-
markers with better sensitivity and specificity for detecting
even moderate drinking during pregnancy. Gestational
alcohol consumption is associated with the onset of FASD
(including FAS), which can lead to physical, cognitive, and
neurobehavioral impairments. Hence, an early diagnosis of
FAS is extremely important for primary prevention with
total abstinence from alcohol during pregnancy and for
secondary prevention to reduce the risk in newborns and
children during later life.
The exact molecular mechanism underlying fetal
developmental defects caused by maternal ethanol con-
sumption remains enigmatic. Unfortunately, the diagnosis
of FAS and fetal alcohol effect is made after birth, when
alcohol damage has become irreversible and permanent.
Laboratory diagnosis can help prevent this damage and
make a valuable contribution to the assessment of prenatal
alcohol abuse. Especially, clinical utility of blood/breath
alcohol, g-glutamyl transferase (GGT), mean corpuscular
volume (MCV), and carbohydrate-deficient transferrin
(CDT) in pregnancy is remarkable. Although none of these
biomarkers has adequate sensitivity and specificity, their
diagnostic accuracy increases when estimated as a panel,
particularly while detecting alcohol abuse in pregnancy
where the presence of several positive biomarkers can be
correlated in the presence of alcohol-related fetal
defects.8
This article briefly reviews the recent literature on bio-
markers as maternal risk factors for FASD and emphasizes
that maternal risk is multidimensional, including factors
related to quantity, frequency, timing of alcohol abuse,
maternal age, number of pregnancies, mother’s frequency
of child birth, body size, body mass index, nutritional sta-
tus, socioeconomic status, metabolism, religion, spiritual-
ity, depression, drug abuse, and social relationships.
Furthermore, a brief description of various biomarkers is
provided as a basic guideline for the clinical management
of FAS during the early stages. Although the first trimester
is considered to be the most vulnerable period, it is now
realized that intrauterine exposure to ethanol may cause
fetal damage throughout the entire gestational period.
Based on the data obtained from the National Epidemio-
logic Survey on Alcohol and Related Conditions, Falk
et al9,10 reported that 21.7% of the sampled population
abused both alcohol and tobacco and 5.6% abused alcohol
along with other drugs. Among women aged 18e24 years,
the rates were 25.5% and 12.5%, respectively.
Individually, alcohol, tobacco, and illicit drugs (cocaine
or amphetamine) are harmful to the developing fetus.
Hence, determining the harm resulting from multiple drug
abuse during pregnancy is a challenging task. Unpredictable
interactive effects of the drugs abused simultaneously have
long-term consequences on the child’s health and devel-
opment. Intrauterine ethanol-exposed adolescents are
highly prone to developing drug dependence, and ethanol
neurotoxicity is augmented by nicotine in these individuals.
14 A. Chabenne et al.By performing micro-positron emission tomography imaging
with 18F-DOPA and 18FdG on cocaine and methamphetamine
(METH)-intoxicated C57BL/6J mice, we discovered that
these illicit drugs of abuse cause a reduction in the striatal
dopaminergic neurotransmission. Uptake of the striatal 18F-
DOPA and myocardial 18FdG was further reduced when
cocaine and METH were administered along with ethanol,
suggesting that alcohol accentuates cocaine and METH
neurotoxicity and may be considered as the gateway to
multiple drug abuse.11 More deleterious consequences in
learning, intelligence, memory, and delayed sensory-motor
learning have been noticed among children whose mothers
consumed alcohol during pregnancy. Particularly, the use of
a combination of alcohol and cocaine is more harmful than
that of each drug individually because of the formation of
the highly toxic metabolite cocaethylene.12,13 Hence, FAS
must be a diagnosis of exclusion, and has to be differenti-
ated from conditions caused by other embryotoxic agents,
such as environmental neurotoxin, domoic acid, malnutri-
tion, zinc deficiency, and genetic syndromes, which share
similar morphological features. In fact, FAS is not a single
entity but represents the most severe form of a spectrum of
disorders, including characteristic craniofacial alterations,
stunted growth, and behavioral abnormalities caused by
geneeenvironment interactions in addition to ethanol.
There is no doubt that alcohol induces deleterious effects
on the developing fetus, and the severity of fetal damage
depends on the strength of alcohol and the frequency of its
consumption during pregnancy. Depending on the fre-
quency of alcohol consumption during pregnancy and the
concentration of alcohol, still birth, preeclampsia, abor-
tion, and fatality have been noticed to occur. In addition to
FAS, maternal alcohol consumption during pregnancy may
cause Trout syndrome, sudden infant death syndrome, and
autism. Various neurotransmitters and their receptors may
be modified and/or impaired in FAS. In particular, dopa-
minergic, cholinergic, g-amino butyric acid (GABA)-ergic,
glutamatergic, and serotonergic systems are impaired in
FAS victims. This suggests that alcohol consumption should
be absolutely prevented at any stage of pregnancy, as it
may seriously affect the synaptic neurotransmission in
some brain regions, which is required for normal learning,
intelligence, memory, and behavior.Definition of a biomarker
A biomarker is a distinct biochemical, genetic, or molecular
characteristic or substance that serves as an indicator of a
particular biological condition or process. According to
Strimbu and Tavel,14 the term “biomarker” refers to a
broad subcategory of medical signs, that is, an objective
indication of the medical state observed from outside the
patient, which can be measured accurately and reproduc-
ibly. Peterson15 provided definitions of state and trait bio-
markers. In brief, a “state biomarker” provides information
about recent drinking activity, where as a “trait biomarker”
provides information about a person’s genetic predisposi-
tion toward alcohol dependence. In general, GGT, alanine
aminotransferase, aspartate aminotransferase (AST), CDT,
N-acetyl-b-hexosaminidase, whole blood-associated acet-
aldehyde, MCV, apolipoprotein J, 5-hydroxytryptophol (5-HTOL), fatty acid ethyl esters (FAEEs), and ethyl glucuro-
nide (EtG) are used as state biomarkers,16e18 whereas
adenyl cyclase activity, GABA, dopamine, b-endorphin, and
serotonin are used as trait biomarkers to determine the
acute or chronic deleterious effects of fetal alcohol
abuse.19e21
Ideal biomarker of FAS
An ideal biomarker for detecting alcohol abuse should have
the following characteristics: (1) the capacity to detect
low-to-moderate levels of drinking over extended periods
of time; (2) a high probability of detecting drinking during
pregnancy (“sensitivity”); (3) a low rate of false-positive
results (“specificity”); (4) easy accessibility of biological
sample by a minimally invasive clinically acceptable pro-
cedure; (5) little or no sample preparation requirement; (6)
a simple, economical analytical procedure of detection;
and (7) ability to provide rapid results. Unfortunately, none
of the presently available biomarkers adequately satisfies
more than one or two of these criteria.
Clinical consequences of intrauterine alcohol
Depending on the strength of alcohol and the frequency of
its consumption during pregnancy, still birth, preeclampsia,
abortion, and fatality have been reported. In addition to
FAS, fetal alcohol can induce Trout syndrome, sudden in-
fant death syndrome, and autism. Adverse clinical conse-
quences of intrauterine alcohol exposure to a developing
fetus are illustrated in Fig. 1.
Classification of FAS biomarkers
In general, FAS biomarkers can be classified as in vitro and
in vivo biomarkers, which can further be subdivided into
clinical, molecular, omic, and imaging biomarkers. At
earlier stages, cord blood, meconium, and urinary bio-
markers can facilitate the assessment of deleterious con-
sequences of FAS. In general, FAS biomarkers can be
divided into the following categories: (1) clinical; (2) mo-
lecular; (3) omic; (4) imaging; (5) meconium; (6) cord
blood; (7) placental; (8) plasma; (9) urinary; and (10)
meconium biomarkers. We have described primarily eight
FAS biomarkers, including clinical, molecular, omic, imag-
ing, meconium, cord blood, anatomical, and neuro-
behavioral biomarkers, which can facilitate early FAS
diagnosis, as illustrated in Fig. 2.
Temporal window of FAS biomarkers
The concentration of the FAS biomarkers depends on the
severity and duration of maternal ethanol abuse. Usually
<1 drink/day is considered low, 2 drinks/day moderate,
and >14 drinks/week severe. Although several biomarkers
have been proposed for the early diagnosis and accurate
clinical evaluation of FAS, their estimation and quantita-
tion for the differential diagnosis has a critical temporal
window. For example, within hours of birth, breath, blood,
and urine alcohol levels can be estimated to assess the
Figure 2 Biomarkers of FAS. FAS biomarkers can be divided
into the following eight major types: (1) clinical biomarkers;
(2) molecular biomarkers; (3) omic biomarkers; (4) imaging
biomarkers; (5) meconium biomarkers; (6) cord blood bio-
markers; (7) anatomical biomarkers; and (8) neurobehavioral
biomarkers. FAS Z fetal alcohol syndrome.
Figure 1 Clinical consequences of intrauterine alcohol. This
diagram illustrates clinical consequences of intrauterine
alcohol exposure to a developing fetus. Alcohol induces dele-
terious effects on the developing fetus, and the severity of
fetal damage depends on the strength and frequency of alcohol
consumption during pregnancy. In general, still birth, pre-
eclampsia, abortion, and fatality have been reported. Fetal
alcohol can also induce fetal alcohol syndrome, Trout syn-
drome, sudden infant death syndrome, and autism.
Biomarkers in fetal alcohol syndrome 15severity of maternal alcohol abuse. Urinary EtG can be
detected within the first 5 days of delivery, whereas CDT
and phosphatidyl ethanolamine (PEth) can be detected
within <3 weeks. GGT and MCV can be detected within <3
weeks, and hair analysis of FAEEs, EtG, and PEth can be
performed within <3 months. Ideally, weeks and months
are the target areas for the development of novel bio-
markers of FAS. Within hours of delivery, the level of
breath, blood, and urine alcohol, even if low, can be
detected. Moderate alcohol consumption may be detected
by estimating CDT and PEth. Urinary ethanol and EtG can
be estimated within weeks, whereas GGT, MCV, meconium
FAEE, hair analysis of FAEE, EtG, and PEth can be detected
within months in the hair, plasma, and meconium samples,
as illustrated in Fig. 3. Furthermore, several in vitro bio-
markers of FAS have been introduced, including MCV,
alanine aminotransferase, FAEE, GGT, acetaldehyde-
derived conjugates, EtG, ethyl sulfate (EtS), AST, de-
rivatives of nonoxidative ethanol metabolism, and PEth to
facilitate early FAS diagnosis and/or treatment. Direct
maternal biomarkers include GGT, AST, alanine amino-
transferase, MCV, CDT, and the ratio of (5-hydroxy tryp-
tophol/5-hydroxy indole acetic acid) have also been
estimated.Trait versus state biomarkers of FAS
Trait biomarkers include platelet adenyl cyclase activity
and increased b-endorphin responsiveness. State bio-
markers are of two types, namely indirect and direct
biomarkers, which can be subdivided into spot or short-term abuse and chronic long-term abuse. For spot or short-
term use, ethanol in blood, breath, and urine; EtG in urine
and blood; FAEE in serum; PEth in blood; EtS and ethyl
phosphate in urine and blood; and b-carboline in urine or
blood can be estimated. For chronic long-term alcohol
abuse, FAEE in hair and meconium, EtG in hair and
meconium, cocoethylene in hair, acetaldehyde adducts of
proteins in erythrocytes in hair, and b-carboline in hair
may be estimated. Direct biomarkers can be subdivided
into spot or short-term biomarkers (5-HTOL/5-HIAA) in
urine. For chronic or long-term use, GGT in urine, alanine
aminotransferase and AST in serum, MCV in blood, CDT in
urine, sialic acid in serum, sialic acid index of serum
apolipoproteins, b-hexosaminidase in the serum, methanol
in blood, and dolicohol in blood and urine can be esti-
mated for the clinical assessment of FAS, as illustrated in
Fig. 4.Clinical biomarkers of FAS
Chronic intake of ethanol during pregnancy can primarily
cause FAS, autism, and sudden infant death syndrome.
Depending on the amount of alcohol consumed and the
frequency of consumption during early stages of preg-
nancy, still birth, abortion, or preeclampsia may occur.
Clinical biomarkers of FAS can be subdivided into
anatomical biomarkers, developmental biomarkers,
neurological biomarkers, delayed motor learning, and
impaired handwriting. In general, anatomical biomarkers
include facial abnormalities, micrognathia, small-size lips,
reduced frontal lobe development, and reduced eye
blinking. In particular, neurological biomarkers of FAS
Figure 3 Temporal window of biomarkers detectability. Different FAS biomarkers can be detected within hours, days, weeks, and
months, depending on the amount of alcohol consumed during pregnancy. Within hours of delivery, breath, blood, and urine
alcohol levels can be detected even at a low concentration of alcohol; moderate alcohol consumption may be detected by esti-
mating % CDT and PEth. Higher concentration of alcohol may have deleterious consequences. Urinary ethanol and ethylene
glucuronide can be estimated within weeks, whereas MCV, GGT, meconium FAEE, and hair analysis of FAEE, ethylene glucuronide,
and phosphatidyl ethanolamine can be detected within months in FAS victims. CDT Z carbohydrate-deficient transferrin;
EtG Z ethyl glucuronide; FAEE Z fatty acid ethyl ester; FAS Z fetal alcohol syndrome; GGT Z gamma glutamyl transferase;
MCV Z mean corpuscular volume; PEth Z phosphatidyl ethanolamine.
16 A. Chabenne et al.include mental retardation, slow learning, reduced intel-
ligence, reduced memory retention, and abnormal
aggressive behavior.Morphological biomarkers of FAS
Not all women who consume alcohol during pregnancy have
children with FASD, as genetic factors, nutritional status,
and body mass index of the mother may also play significant
roles in ethanol teratogenesis. The lack of a convincing mo-
lecular biomarker has hindered FASD research and treat-
ment. However, FASD comprises severe cognitive and
structural birth defects including short stature, small head,
cleft lip/palate, small jaw, wide-set eyes, dental abnor-
malities, and digit abnormalities. Interestingly, mutations in
an inwardly rectifying potassium channel, Kir2.1, cause
similar birth defects as noticed in FASD. In other words, FASD
phenocopies the traits conveyed by Kir2.1 mutations.
Recently, Bates22 reported that alcohol targets Kir2.1 to
cause the birth defects associated with FASD. Clinical, ge-
netic, biochemical, electrophysiological, and molecular ev-
idence also identified Kir2.1 as a molecular target for FASD
development and therapeutic treatment. Recently, Downing
et al23 examined gene expression in embryos and placentae
from C57BL/6J (B6) and DBA/2J (D2) mice following prenatal
alcohol exposure. B6 fetuses were susceptible to morpho-
logical malformations, whereas D2 fetuses were relatively
resistant. These investigatorsmatedmale and female B6 and
D2 mice to produce four embryonic genotypes: true-bred
B6B6, D2D2, reciprocal B6D2, and D2B6. On Gestational Day
9, dams were intubated with 5.8 g/kg ethanol, an isocaloric
amount of maltose dextrin, or nothing. Four hours later,
dams were sacrificed, and embryos and placentae were
harvested. RNA was extracted and hybridized to an Affy-
metrix Mouse Genome microarray chip. Several genes were
differentially expressed in B6 and D2 regardless oftreatment, including genes involved in polysaccharide
binding and mitosis. Altered expression of genes involved in
methylation, chromatin remodeling, protein synthesis, and
mRNA splicing was observed. Altered gene expression in B6
included those involved in mRNA splicing, transcription, and
translation. The lack of strain-specific effects in D2 suggests
that only a few genes induce resistance.
Neuroimaging studies on individuals with FASD have
provided links between prenatal alcohol exposure and
morphological deficits. Yang and colleagues24,25 collected
the structural MRI data from 69 children and adolescents
with FASD and 58 controls, to detect cortical thickness
changes in FASD and their associations with facial dysmor-
phology. Individuals with FASD showed thicker cortices than
controls in frontal, temporal, and parietal regions.
Increased inferior frontal thickness was correlated with
reduced palpebral fissure length. This study suggested the
increase in cortical thickness as a biomarker for impaired
brain development in FASD. The associations between
cortical thickness and dysmorphic measures suggested that
the severity of brain anomalies may be reflected on the
face. Ocular defects have been reported in about 90% of
children with FAS, including microphthalmia, loss of neu-
rons in the retinal ganglion cell (RGC) layer, optic nerve
hypoplasia, and dysmyelination. Estimations of neurons in
the ganglionic cell layer (GCL) and dorsolateral geniculate
nucleus (dLGN), and analysis of RGC morphology were
carried out in transgenic mice exposed to ethanol during
early postnatal life. Dursun and colleagues26 performed this
study in male and female transgenic mice expressing yellow
fluorescent protein under the control of thymus cell antigen
1 (Thy-1) regulator using C57 background. Ethanol (3 g/kg/
day) was administered to pups by intragastric intubation
throughout postnatal Days 3e20. Blood alcohol concentra-
tion (BAC) was measured on postnatal Day 3, Day 10, and
Day 20 after the second intubation. Numbers of neurons in
the GCL and dLGN were quantified on postnatal Day 20
Figure 4 Classification of FAS biomarkers. In general, FAS biomarkers may be divided in two broad categories: (1) trait and (2)
state biomarkers. Trait biomarkers include platelet adenyl cyclase activity and increased b-endorphin responsiveness. State bio-
markers are of two types: indirect and direct biomarkers. Indirect and direct biomarkers can be subdivided into spot or short-term
use and chronic long-term use. For spot or short-term use, we can estimate ethanol in blood breath and urine, EtG in urine and
blood, FAEE in serum, PEth in blood, EtS and EtP in urine and blood, and TICS or b-carboline in urine or blood. For chronic long-term
use, we can estimate FAEE in hair and meconium, EtG in hair and meconium, cocaethylene in hair, acetaldehyde adducts of
proteins in erythrocytes in hair, and b-carboline in hair. Direct biomarkers can be subdivided into spot or short-term use (5-HTOL/5-
HIAA) in urine. For chronic or long-term use, GGT in urine, ALT and AST in serum, MCV in blood, CDT in urine, sialic acid in serum,
sialic acid index of serum apolipoproteins, b-hexosaminidase in the serum, methanol in blood, and dolicohol in blood and urine can
be estimated. ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; CDT Z carbohydrate-deficient transferrin;
EtGZ ethyl glucuronide; EtPZ ethyl phosphate; EtSZ ethyl sulfate; FAEEZ fatty acid ethyl ester; FASZ fetal alcohol syndrome;
GGT Z gamma glutamyl transferase; MCV Z mean corpuscular volume; PEth Z phosphatidyl ethanolamine; 5-HTOL Z 5-
hydroxytryptophol; TICS Z sudden, rapid, nonrhythmic movements.
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altered RGC morphology and decreased the number of
neurons in the GCL and dLGN. The soma was significantly
reduced and dendritic tortuosity increased in RGCs. A
decrease in total dendritic field area and an increase in the
branch angle were also observed. Dendritic elongation and
a decrease in the spine density were observed in the IC
group, as compared to ethanol-exposed and control sub-
jects. No significant effects were observed on the total
retinal area, suggesting that an early postnatal ethanol
exposure affects the development of visual system by
reducing the number of neurons in the GCL and dLGN, and
by altering RGC morphology.
The time of onset of FAS is difficult to determine
because of the challenge associated with in vivo studies of
the peri-implantation stage of embryonic development.
Because embryonic stem cells (ESCs) are derived from
blastocyst-stage embryos, these cells have been used as a
model for investigating early embryonic development.
VandeVoort and coinvestigators27 performed an in vitro
study on ESC lines (ORMES-6 and ORMES-7) of rhesus mon-
keys treated with ethanol, estradiol, or acetaldehyde with
or without estradiol for 4 weeks. Although control ESCs
remained unchanged, abnormal morphology in the ethanol-
and acetaldehyde-treated groups was observed prior to 2
weeks of treatment. Immunofluorescence staining of plu-
ripotency markers (TRA-1-81 and alkaline phosphatase)
indicated a loss of ESC pluripotency in the 1.0% ethanol
group. The ORMES-7 cell line was more sensitive to ethanolthan the ORMES-6 cell line. Estradiol increased sensitivity
to ethanol in both the ORMES-6 and the ORMES-7 cell line.
This study suggested that the effects of ethanol may be
mediated through metabolic pathways regulating acetal-
dehyde formation; however, estradiol-induced increase in
sensitivity to ethanol remains unknown.
In mice, ethanol exposure on gestational Day 7 results in
ventromedial forebrain deficits along with facial anomalies
characteristic of FAS. Godin and coworkers28 explored eth-
anol’s teratogenic effect on the ventromedial forebrain in a
mouse model. Mated C57Bl/6J mice were injected with
2.9 g/kg ethanol or saline twice, at a 4-hour interval, on
their 7th day of pregnancy. On gestational Day 12.5, Day 13,
and Day 17, control and ethanol-exposed specimens were
collected to assess morphological changes. Cerebral hemi-
spheres (forebrains) of ethanol-exposed embryos were too
close in proximity or rostrally united, with enlarged
foramina of Monroe or united lateral ventricles, and hip-
pocampal and ventromedial forebrain deficiency. On
gestational Day 12.5, in control and ethanol-exposed em-
bryos, in situ hybridization confirmed the selective loss of
ventromedial region. Immunohistochemical labeling of
oligodendrocyte progenitors with Olig2, a transcription
factor necessary for their specification and of GABA, showed
reductions. Somatostatin-expressing interneurons were
dysmorphic in the ethanol-exposed fetuses. In addition,
facial abnormalities, micrognathia, small lip size, reduced
frontal lobe development, and reduced eye blinking were
observed in the progeny with fetal alcohol exposure.
18 A. Chabenne et al.Neurological biomarkers of FAS
In general, neurological biomarkers of FAS include mental
retardation, reduced memory retention, slow learning,
abnormal behavior, reduced intelligence, and aggressive
behavior. Multicenter neuroimaging trials, consortia, and
collaborations enabled the acquisition of data that can be
used to predict clinical outcomes as well as treatment op-
tions for FAS.29 Symptoms of FAS include neurological and
immunological dysfunctions linked to cell reduction. Hao
and colleagues30 exposed CD34þ human fetal liver he-
matopoietic stem cells (HSCs) and CD133þ/nestinþ human
neural stem cells (NSCs) to 0.1e10 mM ethanol, which
induced deleterious effects on NSCs but had no significant
effects on HSCs. The colony-forming ability of NSCs was
completely inhibited by 5 mM ethanol treatment, whereas
HSCs were unaffected by even 20 mM ethanol, suggesting
selective sensitivity of NSCs to ethanol. Protein kinase C
(PKC) isoenzyme expression was also differentially affected
by ethanol in NSCs and HSCs. These observations also
explain the lack of hematopoietic problems in FAS.
Molecular biomarkers of FAS
Lee and colleagues31 performed differential mRNA analyses
to characterize the etiology and discover potential molec-
ular biomarkers for FAS. Out of approximately 1080 mRNA
transcripts in mouse embryos, the levels of three mRNAs
were altered. Two of these mRNAs (1 novel and 1 encoding
heat shock protein-47) were also modulated by 3-
methylcholanthrene. The third mRNA, encoding a-tropo-
myosin, was specifically upregulated by ethanol. The level
of a-tropomyosin, a brain-specific isoform, was elevated in
the ethanol-exposed embryos. Several well-known medi-
cations, such as aspirin, cimetidine, and ranitidine, interact
with alcohol metabolism, leading to increased BAC.32e34
Given that BAC is a reliable predictor of the severity of
alcohol-mediated brain injury in preclinical studies, any
drug that interferes with alcohol metabolism and results in
an increase in BAC may be a cofactor in increasing alcohol-
mediated damage.35,36 Johnson and colleagues37 showed
that cigarette smoking reduces peak BAC in humans. Pre-
clinical studies have supported these findings.38,39 A
decrease in BAC in the presence of nicotine may suggest
less harmful effects of alcohol; however, if someone desires
to experience the “high” from alcohol or drink to the point
of inebriation, this decrease in BAC may promote additional
alcohol abuse, which may lead to an accumulation of
acetaldehyde, a toxic metabolite that may cause further
damage to the developing fetus. Recently, Ismail and col-
leagues40 reviewed the teratogenic effects of alcohol,
strategies for detecting maternal alcohol consumption,
identification of fetal biomarkers, and prevention pro-
cedures for FAS. Furthermore, Roehsig and coworkers41
developed a method for the determination of eight FAEEs
(ethyl laurate, ethyl myristate, ethyl palmitate, ethyl pal-
mitoleate, ethyl stearate, ethyl oleate, ethyl linoleate, and
ethyl arachidonate) in meconium samples. FAEEs could be
detected in alcohol-exposed newborns. These could also be
detected in some nonexposed newborns, although the
concentrations were lower than those measured in exposedcases. Dutta and colleagues42 used amniotic fluid for
biomarker analyses to discriminate between FAS-positive
and FAS-negative pregnancies in mice. B6J and B6N litters
were treated with alcohol or saline on Day 8 of gestation.
Preliminary characterization revealed reduced peaks to a-
fetoprotein, supporting clinical observations. Furthermore,
Trave´s and coworkers43 proposed apolipoprotein A-IV
(apoA-IV) as a biomarker for evaluating the effects of in-
trauterine ethanol on the development of the intestine.
These investigators estimated serum biomarkers to deter-
mine the structural integrity of the intestine. Exposure to
ethanol in utero reduced the levels of apoA-IV in serum at
birth, regardless of body weight, suggesting that circulating
apoA-IV could be used as a biomarker of FAS. Barr and
colleagues44 reported that rodents that are prenatally
exposed to ethanol exhibit a wide range of cognitive defi-
cits, including impairments in memory, attention, and ex-
ecutive function. These investigators measured levels of
presynaptic proteins complexin I and II in a rat model of
prenatal ethanol exposure, as levels of these proteins are
altered in cognition-related synaptic plasticity. Prenatal
exposure to ethanol did not alter presynaptic proteins in
the hippocampus or levels of synaptophysin; however,
these rats displayed reduced levels of complexin I and II in
the prefrontal cortex.
Lee and colleagues31 determined the molecular mecha-
nisms underlying alcohol-induced ocular anomalies in Xen-
opus embryos, exposed to various concentrations
(0.1e0.5%) of alcohol, and the subsequent effects on eye
development and eye biomarker gene expression.
Furthermore, Peng and coworkers45 investigated the role of
reactive oxygen and nitrogen species in FAS-associated
ocular injury, using antioxidant enzymes, catalase, and
peroxiredoxin 5, which were overexpressed in the blasto-
meres of Xenopus embryos. Alcohol caused micro-
phthalmia, incomplete closure of the choroid fissure,
malformation of the retina in 40% of the eyes, and reduced
expression of eye biomarker genes, of which TBX5, VAX2,
and Pax6 were highly vulnerable. Overexpression of mito-
chondrial catalase and peroxiredoxin 5 restored the
expression of these biomarkers and decreased ocular mal-
formation. Although these antioxidant enzymes reduced
the production of alcohol-induced reactive oxygen species,
only peroxiredoxin 5 inhibited the formation of reactive
nitrogen species, suggesting that oxidative and nitrative
stresses contribute to alcohol-induced fetal ocular injury.Meconium biomarkers of FAS
The biomarkers of FAS that can be detected from meco-
nium include FAEE, EtG, PEth, and EtS. Their estimation
can provide a reliable measure of alcohol consumption
during pregnancy, as these are relatively stable and can be
estimated even after 2e3 months of delivery. In addition to
self-reports and questionnaires, biomarkers are of rele-
vance in the diagnosis and treatment of alcohol abuse dis-
orders.46 Traditional biomarkers such as GGT or MCV are
indirect biomarkers and are influenced by age, gender, and
non-alcohol-related diseases, whereas EtG, EtS and PEth
are direct metabolites of ethanol and hence represent
useful diagnostic tools for identifying alcohol abuse more
Biomarkers in fetal alcohol syndrome 19accurately. These biomarkers remain positive in serum and
urine for a considerable length of time. They are applied in
routine clinical use, in emergency room settings, for
providing proof of abstinence in alcohol rehabilitation
programs, for detecting offenders driving under alcohol
influence, in workplace testing, for assessing alcohol intake
during liver transplantation, and for evaluating FAS. Due to
these properties, these biomarkers may open up further
avenues for prevention, interdisciplinary cooperation,
diagnosis, and treatment of alcohol-related disorders.
Natekar and coinvestigators47 studied clinical cases of both
cocaine and alcohol abuse, and determined hair cocaine,
benzoylegconine, Cocaethylene (CE), and FAEEs. Concen-
trations of cocaine and benzoylegconine were associated
with increased FAEE. The positive predictive value of CE
was 0.66 for excessive drinking and 0.76 for chronic drink-
ing among cocaine addicts. The negative CE value ruled out
excessive alcohol consumption. Positive hair CE results had
high specificity for chronic alcohol consumption among
cocaine addicts. Thus, identification of CE in the hair of
pregnant women who abuse cocaine can serve as a
biomarker for FASD.
In the past few years, nonoxidative ethanol metabolites
have received attention because of their specificity andwide
time window of detection in nonconventional matrices from
pregnant mothers (oral fluid and hair) and from fetuses or
newborns (neonatal hair, meconium, placenta, and umbili-
cal cord). Joya and colleagues48 reviewed analytical pro-
cedures for the determination of these biomarkers during
pregnancy and related prenatal ethanol exposure. These
investigators reported that fetal alcohol disorders are pre-
ventable, but self-reported alcohol consumption could be
misleading and impede effective treatment. Their study
evaluated the relationship between blood PEth and alcohol
abuse. Alcohol was estimated by self-report methods in 80
nonpregnant women aged 18e35 years. PEth had a positive
linear association with the amount of alcohol consumed, and
was detectable in 93% of individuals consuming an average of
two or more drinks per day. Increasing evidence indicates
that neurons and glia are direct targets of alcohol, but may
also be vulnerable to molecules produced in peripheral sys-
tems as a result of alcohol exposure. Diagnostics and thera-
pies can take advantage of these biomarkers, and these may
be applicable to central nervous system pathology (CNS) in
FASD.49 A study was performed to evaluate the experience,
knowledge, and confidence of Italian and Spanish neo-
natologists and pediatricians with respect to the diagnosis of
FAS and FASD, and to evaluate awareness of maternal
drinking patterns during pregnancy.6 A multiple-choice
questionnaire was e-mailed to Italian neonatologists, and
presented to Italian and Spanish pediatricians during the
National Congress. The response rate was 16% (63/400) for
the Italian neonatologists, whereas a total of 152 Spanish and
41 Italian pediatricians completed the questionnaire. Over
90% of the physicians declared that FAS is an identifiable
syndrome, and over 60% of them identified at least one of the
most important features of FAS. Although over 60% Italian
and around 80% Spanish responders were aware that ethanol
abuse in pregnancy is dangerous, approximately 50% Italian
and 40% Spanish responders allowed women to drink a glass
of wine or beer during pregnancy. Neonatologists and pedi-
atricians rated confidence in the ability to diagnose FAS andFASD as low. Over 50% of responders felt the need for more
knowledge regarding the identification of FAS and FASD in
newborns and children. However, all the responders did not
feel confident about diagnosing FAS and FASD accurately,
indicating the dire need for further studies on the novel
discovery of FAS biomarker(s).
To study the effect of in utero alcohol exposure on insulin-
like growth factor (IGF) and leptin during infancy and child-
hood, Aros and colleagues50 identified heavily drinking
pregnant women who consumed on average four or more
drinks of ethanol per day (48 g/day) and assessed growth in
69 of their offspring and control group of 83 children by
measuring serum IGF-I, IGF-II, IGF-binding protein 3, and
leptin at 1 month and 1-, 2-, 3-, 4-, and 5-years of age. IGF-II
levels increased with age in both groups, but levels were
higher in ethanol-exposed children at 3-, 4-, and 5- years of
age. IGF-I levels were higher at 3 years and 4 years and leptin
levels were lower at 1 year and 2 years. A lower correlation
between IGF-I and growth parameters suggested that expo-
sure to ethanol during pregnancy increases IGF-I and IGF-II
and decreases leptin during early childhood, and that lep-
tin may be explored as a potential biomarker for prenatal
alcohol exposure. Recent studies have shown that alcohol
alters DNA methylation patterns and inhibits NSC differen-
tiation,51 whereas Emodin prevents ethanol-induced devel-
opmental anomalies in culturedmouse fetus.52 Van Horn and
Toga29 performed a study to review multicenter neuro-
imaging trials and their implications for clinical treatment.
These authors reported that geographic factors underlying
diseased populations coupled with complementary neuro-
imaging research has increased neuroimaging trials and
consortia. In this contest, neuroimaging has become a major
focus for multi-institutional research on FAS. Bakhireva and
colleagues53 performed a study to evaluate the feasibility
and cost of Prenatal alcohol exposure (PAE) screening by
measuring PEth in dried blood spot (DBS) cards. Their findings
suggested that PAE screening by PEth in DBS is simpler and
less expensive as compared to other screening approaches.
Moreover, screening by PEth analysis fromDBS cardswas cost
efficient. The relationship betweenalcohol consumption and
PEth was stronger in women with recent heavy drinking.
Hence, PEth is a sensitive indicator of moderate and heavy
alcohol consumption, and may complement the use of self-
report alcohol screens when additional objective bio-
markers of alcohol abuse are desirable. However, choosing a
valid cutoff concentration for PEth to differentiate various
levels of alcohol consumption may not be feasible.54Cord blood biomarkers of FAS
Accurate confirmation of PAE is required as a diagnostic
criterion for the majority of children who do not manifest
the physical features associated with FAS. Cord blood bio-
markers of FAS including FAEEs, PEth, EtG, and EtS can be
detected and estimated.Omic biomarkers of FAS
Although several molecular and genetic biomarkers have
been discovered, none of them is selective. Omic
20 A. Chabenne et al.biomarkers of FAS can be divided into proteomic, metab-
olomics, lipidomic, glycomic, and genomic biomarkers.Imaging biomarkers of FAS
Imaging biomarkers of FAS include computed tomography
biomarkers, positron emission tomography imaging bio-
markers, MRI imaging and MR spectroscopy, and ultra-
sound imaging. FAS and related disorders (FASD) cause
physical and mental damages to the affected individuals.
Previously, histological studies in animals reported cere-
bral cortical abnormalities that result from prenatal
ethanol exposure. Additionally, MRI identified abnormal-
ities in the cerebral cortices of children and adolescents.
However, there is still a need to bridge the gap between
human MRI and animal histological studies. Leigland and
colleagues55 performed postmortem MRI experiments on
rodents, during time periods relative to late human
gestation through adulthood, to characterize anomalies
associated with FASD throughout development. By deter-
mining how histologically identified abnormalities are
manifested in MRI during the critical early time points,
neuroimaging-based biomarkers of FASD can be identified
at much earlier ages in humans, thus reducing the impact
of these disorders. Cerebral cortical volume, thickness,
and surface area were characterized by MRI in rat pups
born from dams that were ethanol treated, maltose/
dextrin treated, or untreated throughout the gestational
period at six developmental time points (1e60 days).
Brain volume, cortical volume, cortical thickness, and
cortical surface area were reduced following prenatal
exposure to ethanol. Cortical surface area and cortical
thickness results contributed to interpreting effects of
prenatal ethanol exposure on cerebral cortical develop-
ment. Additionally, regional cortical thickness analyses
suggested that primary sensory areas are particularly
vulnerable to gestational ethanol exposure. Structural MRI
measurements were in accordance with histological
studies performed in animal models of FASD, suggesting
that MRI is sensitive enough to detect neuroanatomical
defects of fetal ethanol exposure on the development of
cerebral cortex during late gestation in humans. This
study provided a link between animal histological data
and human MRI data. Ikonomidou and colleagues56 re-
ported that ethanol treatment on postnatal Day 7 (P7)
causes brain cell death and can be used as a model of late
gestational alcohol exposure. To investigate the long-term
effects of P7 ethanol treatment on adult brain, mice
received two doses of either saline or ethanol on P7
(2.5 g/kg, S.C., 2 hours apart), and were assessed as
adults (P82) for brain volume and cellular architecture.
MRI revealed that P7 ethanol-exposed adult mice had
reduced total brain volume (4%) with reduced brain re-
gions. Reduced frontal cortical parvalbumin immunore-
active interneurons and Cux1 þ IR layer II pyramidal
neurons were observed in both sexes. Biomarkers of adult
hippocampal neurogenesis differed between sexes, with
only ethanol-treated males showing increased double-
cortin and Ki67 expression in the dentate gyrus, with
increased neurogenesis compared to controls, suggesting
that P7 ethanol treatment causes persistent reductions inadult brain volume and frontal cortical neurons in both
males and females. However, increased adult neuro-
genesis was observed in males, but not in females, which
is consistent with differential adaptive responses to P7
ethanol toxicity between the sexes. Thus, 1 day of ethanol
exposure is sufficient to cause persistent adult brain
dysmorphology.57MRS biomarkers of FAS
MRS biomarkers of FAS include N-acetyl aspartate (indicator
of brain regional neuronal density); choline (a precursor of
the neurotransmitter); acetyl choline, implicated in
learning memory and in the synthesis of glycer-
ophosphocholine (involved in membrane synthesis); and
glutamate (which is significantly reduced in FAS). Gluta-
mate is a precursor for the synthesis of GABA (an inhibitory
neurotransmitter), and creatine is required for high-energy
phosphate synthesis. Reduced taurine, glutathione,
myoinositol, and N-methyl D-aspartic acid receptor exci-
totoxicity have also been observed in the FAS. Methioni-
neehomocysteine cycle may have serious effects on the
protein, DNA, and histone methylation during FAS. Several
other neurochemicals may be altered in FAS and can be
estimated by magic angle spinning high-resolution MRS
analysis (beyond the scope of this review). Urinary analysis
of EtS can be made by high-performance liquid chroma-
tography, in addition to the estimation of brain regional
concentrations of N-acetyl aspartic acid (NAA), choline,
creatine, and glutamate by MRS to confirm FAS diagnosis.FAS and depression
It has been shown that women who drink heavily and who
bear children with FASD are likely to have a history of heavy
drinking in their families of origin and procreation and also
in their peer groups.58 Depression is a common complaint
among mothers of children with FASD.59e61 Women who
bear FASD children are also heavy drinkers. Mothers of FASD
children in some countries use other drugs in addition to
alcohol. Moreover, smoking among mothers of FASD chil-
dren and drinkers may also affect the mood. We recom-
mended tryptophan-rich to alleviate symptoms of
depression as it happens due to a depletion of brain
regional serotonin (5-HT).62 As such 5-HT cannot pass
through the bloodebrain barrier. However, its precursor,
tryptophan, can easily pass through the bloodebrain bar-
rier, which in the presence of pyridoxine (vitamin B6) fa-
cilitates the synthesis of brain regional 5-HT by
decarboxylation of 5-hydroxy tryptophan. Hence, a diet
rich in tryptophan may alleviate symptoms of depression,
particularly in pregnant women consuming alcohol. Very
few studies are available in this direction.Conflicts of interest
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